Literature DB >> 17124704

Molecular characterization of rpoB gene mutations in rifampicine-resistant Mycobacterium tuberculosis isolates from tuberculosis patients in Belarus.

Leonid P Titov1, Saeed Zakerbostanabad, Veranika Slizen, Larisa Surkova, Mohammad Taghikhani, Ahmadreza Bahrmand.   

Abstract

The aim of this study was to investigate the frequency, location and type of rpoB mutations in Mycobacterium tuberculosis isolated from patients in Belarus. Tuberculosis cases are increasing every year in Belarus. Moreover, resistance to anti-tuberculosis drugs, especially to rifampicine, has increased. In this study, 44 rifampicine-resistance M. tuberculosis clinical isolates (including multidrug-resistant isolates) were subjected to DNA sequencing analysis of the hypervariable region (hot-spot) of the rpoB gene originating from different geographical regions in Belarus. Sixteen different types of mutations were identified. The most common point mutations were in codons 510 (47.7%), 526 (45.5%), 523 (40.86%) and 531 (29.5%). Eleven isolates (27.7%) carried one mutation and 23 (52%), 7 (16%), 3 (7%) of isolates carried 2, 3 and 4 mutations, respectively. A characteristic, prominent finding of this study was high frequency of multiple mutations in different codons of the rpoB gene (27.7%) and also the detection of unusual types of mutations in the 510 codon, comprising CAG mutations (deletion or changing, to CTG, CAC or CAT). In our study, the change TTG in codon 531 was found in 92% of isolates and the change TGC in 8% of isolates. A TAC change in codon 526 was not found, but the GAC change was found in all isolates. Isolates of M. tuberculosis isolated in Belarus were characterized by the wide spectrum of the important mutations and might belong to the epidemic widespread clones.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17124704     DOI: 10.1002/biot.200600153

Source DB:  PubMed          Journal:  Biotechnol J        ISSN: 1860-6768            Impact factor:   4.677


  6 in total

1.  Extremely high prevalence of multidrug resistant tuberculosis in Murmansk, Russia: a population-based study.

Authors:  J Mäkinen; M Marjamäki; M Haanperä-Heikkinen; H Marttila; L B Endourova; S E Presnova; V Mathys; P Bifani; R Ruohonen; M K Viljanen; H Soini
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-03-11       Impact factor: 3.267

2.  High-level rifampin resistance correlates with multiple mutations in the rpoB gene of pulmonary tuberculosis isolates from the Afghanistan border of Iran.

Authors:  Ahmad Reza Bahrmand; Leonid P Titov; Alireza Hadizadeh Tasbiti; Shamsi Yari; Edward A Graviss
Journal:  J Clin Microbiol       Date:  2009-09       Impact factor: 5.948

3.  Study of Genetic Evolution in Mycobacterium tuberculosis Isolates from Patients with Active Pulmonary Tuberculosis in the Iran and Belarus.

Authors:  Saeed Zaker Bostanabad; Mehdi Shekarabei; Seyed Ali Nojoumi; Esmaeil Jabbarzadeh; Mostafa Ghalami; Vahid Molla Kazemi; Mostafa Gholi Beigdeli; Mohammad Karim Rahimi; Mohammad Bossak; Evgeni Romanovich Sagalchyk; Larisa Konstantina Surkova; Aksana Mikhaelovna Zalutska; Veronika Slizen; Leonid Petrovich Titov
Journal:  Open Microbiol J       Date:  2011-07-04

4.  Pattern recognition and cellular immune responses to novel Mycobacterium tuberculosis-antigens in individuals from Belarus.

Authors:  Raija K Ahmed; Zoyia Rohava; Kithiganahalli N Balaji; Sven E Hoffner; Hans Gaines; Isabelle Magalhaes; Alimuddin Zumla; Alena Skrahina; Markus J Maeurer
Journal:  BMC Infect Dis       Date:  2012-02-15       Impact factor: 3.090

5.  Investigation of the rpoB Mutations Causing Rifampin Resistance by Rapid Screening in Mycobacterium Tuberculosis in North-East of Iran.

Authors:  Amir Tajbakhsh; Faezeh Ghasemi; Seyedeh Zohre Mirbagheri; Mastoureh Momen Heravi; Mehdi Rezaee; Zahra Meshkat
Journal:  Iran J Pathol       Date:  2018-09-25

6.  Antibiotic resistance by high-level intrinsic suppression of a frameshift mutation in an essential gene.

Authors:  Douglas L Huseby; Gerrit Brandis; Lisa Praski Alzrigat; Diarmaid Hughes
Journal:  Proc Natl Acad Sci U S A       Date:  2020-01-28       Impact factor: 11.205

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.